Lu Lu, Yige Qiu, Jiayu Wu, Wei Dou, Jing Yang, Bo Zhang
RNA therapeutics offer considerable potential for cancer treatment. Their therapeutic application, however, remains limited by rapid degradation, inefficient cellular uptake, and restricted intracellular release. Extracellular vesicles (EVs) are cell-derived membrane vesicles that have been exploited as promising vehicles for drug delivery due to their high biocompatibility and low immunogenicity, whereas liposomes and lipid nanoparticles provide tunable lipid composition and efficient loading of exogenous nucleic acids. Combining these carriers has led to EV-lipid hybrid systems designed to integrate their complementary properties. This review summarizes recent advances in EV-lipid hybrids for cancer therapy and organizes the reported systems according to their structural architecture and preparation. EV-liposome fusion hybrids, EV-lipid nanoparticle hybrids, and EV membrane-integrated lipid nanocarriers are discussed in relation to their RNA-loading strategies and representative therapeutic designs. The review also examines the key processes involved in functional RNA delivery and summarizes representative applications across different cancer types. Challenges associated with safety evaluation are also discussed, together with future directions for clinical translation. Overall, EV-lipid hybrids represent a promising strategy for RNA-based cancer therapy.